NCT06904482 Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
| NCT ID | NCT06904482 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Case Comprehensive Cancer Center |
| Condition | aGVHD |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2025-08-13 |
| Primary Completion | 2027-02-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 36 participants in total. It began in 2025-08-13 with a primary completion date of 2027-02-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.
Eligibility Criteria
Inclusion Criteria: * Participants with the following hematologic malignancies: * Acute myelogenous leukemia (AML): High-risk AML including: * Antecedent hematological disease (e.g., myelodysplasia (MDS)) * Treatment-related * Complete Remission (CR1) with poor or intermediate-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, TP53 mutations, complex cytogenetics) * Participants must be in CR1, CR2, CR3 or CRi * Acute lymphoblastic leukemia (ALL) * High-risk CR1 including: * Poor-risk cytogenetics (e.g., t(9;22)or 11q23 rearrangements) * Presence of minimal disease by flow cytometry or PCR or Clonoseq after 2 or more cycles of chemotherapy * No CR within 4 weeks of initial treatment * Participants in CR2 or beyond * Participants must be in CR1, CR2, CR3, or CRi * Myelodysplastic syndromes (MDS), Intermediate, High or Very High Risk by the revised international prognostic scoring system (IPSS-R) or treatment related MDS * High-risk lymphoma * Age \> 18 years * Participants without a suitable HLA-matched related or unrelated donor CASE9Z24 Page 17 Version dated 12.16.2025 * Participants with the following suitable grafts: * A 4-8/8 HLA high resolution matched cord blood unit with a cell dose of 1.0x105 CD34 cells/kg. * A haplo-identical donor with a goal cell dose of \> 4.0x106 CD34cells/kg (minimum 2 x106 CD34 cells/kg) * Concurrent Therapy for Extramedullary Leukemia or CNS Lymphoma: Concurrent therapy or prophylaxis for testicular leukemia, CNS leukemia including standard intrathecal chemotherapy and/or radiation therapy will be allowed as clinically indicated. Such treatment may continue until the planned course is completed. Participants must be in CNS remission at the time of protocol enrollment if there is a history of CNS involvement. Maintenance therapy after transplant is allowed. * Participants must have the ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Participants with inadequate Organ Function as defined by: * Creatinine clearance \< 40ml/min (Cockcroft-Gault) * Bilirubin \> 2X institutional upper limit of normal unless Gilbert syndrome * AST (SGOT) \> 3X institutional upper limit of normal * ALT (SGPT) \> 3X institutional upper limit of normal * Pulmonary function: DLCOc \< 60% * Cardiac: left ventricular ejection fraction \< 40% * ECOG \<2 * Participants with uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant or breastfeeding women are excluded from this study because chemotherapy involved with RIC have the significant potential for teratogenic or abortifacient effects. * Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data. * Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds. * Prior autologous stem cell transplant or CAR-T within the preceding 6 months or prior allogeneic transplant.
Contact & Investigator
Leland Metheny, MD
PRINCIPAL INVESTIGATOR
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center
Frequently Asked Questions
Who can join the NCT06904482 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying aGVHD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06904482 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06904482 currently recruiting?
Yes, NCT06904482 is actively recruiting participants. Contact the research team at Leland.Metheny@uhhospitals.org for enrollment information.
Where is the NCT06904482 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT06904482 clinical trial?
NCT06904482 is sponsored by Case Comprehensive Cancer Center. The principal investigator is Leland Metheny, MD at Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center. The trial plans to enroll 36 participants.